Abstract: A network for an aircraft including a data line and network access devices, a first interface and at least one second interface and connected to the data line via the first interface. Identifiers are assigned to the second interfaces in pairs. The access devices receive and/or transmit data in first data frames having a fixed format and first portion and second portions. The network access devices transmit second data frames and, for each second interface, a sequence of third data frames received on the second interfaces, the network access device including a first processing unit to insert the second data frames in the first portion of the first data frames, split each third data frame into fragment frames, including a part of the respective third data frame and reassembly information allowing regeneration of the third data frame from the fragment frames, and insert the fragment frames into the second portions.

Abstract: A network for an aircraft including a master device and slave devices connected in daisy-chain arrangement series. Each slave device has a unique identifier. The master transmits polling data packets along the slave devices, each including only one identifier. Polling data packets are transmitted in successive sequences, each including for each slave device only one polling data packet and including the polling data packets in a predetermined order. Each slave device includes a first data interface for connection in an upstream direction, a second data interface for connection in the downstream direction, and a processing unit to compare for each received polling data packet the identifier thereof with the identifier of the respective slave device, and output a response data packet to the master device if the two identifiers match, and forward the polling data packet to the second interface at least if the two identifiers do not match.

Abstract: A network for an aircraft including a data line and network access devices, a first interface and at least one second interface and connected to the data line via the first interface. Identifiers are assigned to the second interfaces in pairs. The access devices receive and/or transmit data in first data frames having a fixed format and first portion and second portions. The network access devices transmit second data frames and, for each second interface, a sequence of third data frames received on the second interfaces, the network access device including a first processing unit to insert the second data frames in the first portion of the first data frames, split each third data frame into fragment frames, including a part of the respective third data frame and reassembly information allowing regeneration of the third data frame from the fragment frames, and insert the fragment frames into the second portions.

Abstract: A network for an aircraft including a master device and slave devices connected in daisy-chain arrangement series. Each slave device has a unique identifier. The master transmits polling data packets along the slave devices, each including only one identifier. Polling data packets are transmitted in successive sequences, each including for each slave device only one polling data packet and including the polling data packets in a predetermined order. Each slave device includes a first data interface for connection in an upstream direction, a second data interface for connection in the downstream direction, and a processing unit to compare for each received polling data packet the identifier thereof with the identifier of the respective slave device, and output a response data packet to the master device if the two identifiers match, and forward the polling data packet to the second interface at least if the two identifiers do not match.

Abstract: The present invention relates to compounds of formula (I) which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract: The present invention relates to piperidinesulfonylureas and piperidinesulfonylthioureas of formula I, in which A, X, R(1), R(2) and R(3) have the meanings indicated in the claims. The compounds of formula I are valuable active pharmaceutical ingredients which show in particular an inhibiting effect on ATP-sensitive potassium channels of the cardiac muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as coronary heart disease, arrhythmias, cardiac insufficiency, cardiomyopathies or reduced contractility of the heart or for the prevention of sudden cardiac death. The invention further relates to processes for preparing the compounds of formula I, their use and pharmaceutical compositions comprising them.

Abstract: The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

Abstract: The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

Abstract: The present invention is directed to a compound of formula I: or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to their use to treat described diseases where the substituents are as described in the specification.

Abstract: The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

Abstract: The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

Abstract: The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

Abstract: The present invention provides a process for identifying substances that modulate the activity of hyperpolarization-activated cation channels, and the use of this process.

Abstract: The present invention is directed to a compound of formula I: or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to their use to treat described diseases where the substituents are as described in the specification.

Abstract: The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

Abstract: The present invention relates to piperidinesulfonylureas and piperidinesulfonylthioureas of formula I, in which A, X, R(1), R(2) and R(3) have the meanings indicated in the claims. The compounds of formula I are valuable active pharmaceutical ingredients which show in particular an inhibiting effect on ATP-sensitive potassium channels of the cardiac muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as coronary heart disease, arrhythmias, cardiac insufficiency, cardiomyopathies or reduced contractility of the heart or for the prevention of sudden cardiac death. The invention further relates to processes for preparing the compounds of formula I, their use and pharmaceutical compositions comprising them.

Abstract: The present invention provides a process for identifying substances that modulate the activity of hyperpolarization-activated cation channels, and the use of this process.

Abstract: The present invention relates to compounds of formula (I) which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract: The invention relates to p-thienylbenzylamides of formula (I): in which R(1), R(2), R(3), R(4), R(5), R(6) and X have the meanings given in the description. The compounds of formula (I) are potent agonists of angiotensin-(1-7) receptors and are useful as pharmaceutically active compounds to treat and/or prevent hypertension; cardiac hypertrophy; cardiac insufficiency; coronary heart diseases, such as angina pectoris; and endothelial dysfunction or endothelial damage as a consequence, for example, of atherosclerotic processes or in association with diabetes mellitus.

Abstract: The present invention provides a process for identifying substances that modulate the activity of hyperpolarization-activated cation channels, and the use of this process.